Medical Oncologist
CION Cancer Clinics
Immunotherapy alone for liver cancer: when one drug is enough | CION Cancer Clinics
Immunotherapy is sometimes given as a single drug for primary liver cancer, but most people are first offered a combination. A single drug is kept for people who cannot safely take a pair, or for later, after tablets stop working. This page explains which drugs are used alone, how the team chooses between one drug and two, and who should not have immunotherapy on its own. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Is immunotherapy ever given on its own for liver cancer?
- Which immune drugs are used alone in liver cancer?
- How does the team decide between one drug and two?
- One immune drug or a combination: what changes?
- Who should not have immunotherapy alone?
- What this page cannot tell you
- Common questions about immunotherapy alone for liver cancer
The short answer
Is immunotherapy ever given on its own for liver cancer?
Yes, but less often than in combination. For primary liver cancer (hepatocellular carcinoma, or HCC) the usual first choice is a pair of drugs, either atezolizumab plus bevacizumab or durvalumab plus tremelimumab. A single immune drug is kept for people who cannot safely take a pair, or for use later, after tablets have stopped working.
Why a single drug is sometimes the right answer
Some people are too unwell, too old or too frail for two drugs at once. Others have a bleeding risk that rules out bevacizumab and a reason to avoid stronger immune side effects. For them, one immune drug can offer real control of the cancer with a gentler side-effect load. In trials, single-drug immunotherapy did about as well as sorafenib tablets, while the pairs did better.
Which cancer this page is about
This page is about cancer that started in the liver. If the cancer spread to the liver from another organ, the drugs follow that original cancer. Read about secondary cancer in the liver instead.
A single drug is not a weaker choice made to save money. It is a deliberate choice for a particular person.The names you may hear
Which immune drugs are used alone in liver cancer?
Several names come up in searches. They are not used in the same way, and one of them is not used alone at all.
Durvalumab
Studied on its own in the same large trial that tested it with tremelimumab. Alone, it was about as effective as sorafenib, with fewer of the side effects that tablets bring. It is sold in India.
Nivolumab and pembrolizumab
These have been used mainly after sorafenib or lenvatinib, as a later step. The trial results were mixed, so guidelines treat them as options rather than standards. Both are available in India, including lower-cost versions of nivolumab.
Atezolizumab
In advanced liver cancer, atezolizumab is given with bevacizumab, not alone. If a report says atezolizumab, ask whether bevacizumab is part of the plan.
Atezolizumab alone has no standard role in advanced HCC.Newer drugs
Other immune drugs have been tested against sorafenib in trials, some with encouraging results. Approval and supply in India vary, so ask your oncologist what can actually be obtained here.
Not sure whether this applies to you?
Ask an oncologistHow the decision is reached
How does the team decide between one drug and two?
Liver function is checked
Bilirubin, albumin, INR and any fluid in the abdomen give the Child-Pugh score. Most evidence is in Child-Pugh A. With Child-Pugh B a single drug is sometimes chosen because it is easier to tolerate.
Bleeding risk is assessed
An endoscopy looks for varices, the swollen veins in the food pipe that liver disease causes. High-risk varices or a recent bleed make bevacizumab unsafe.
Fitness and other illnesses are weighed
Heart, kidney and lung health, diabetes and how active the person is day to day all count. A frail person may manage one drug well and two drugs badly.
The tumour board agrees a plan
Medical, surgical and radiation oncologists review the scans and reports together, and then explain the reasons to you and your family before anything starts.
Side by side
One immune drug or a combination: what changes?
A single immune drug
A combination
In trials, roughly as effective as sorafenib
In trials, better than sorafenib
Fewer serious immune side effects overall
More side effects, and bleeding risk with bevacizumab
Often chosen for frailer people or weaker liver function
Usually kept for people with Child-Pugh A and good fitness
Also used later, after tablets stop working
Usually the first drug treatment offered
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being honest
Who should not have immunotherapy alone?
Someone fit enough for a combination, with Child-Pugh A liver function and no bleeding concern, is usually better served by one of the pairs. Choosing a single drug in that situation means giving up the better result the pairs showed in trials.
When immune drugs are not safe at all
After a liver transplant, immune drugs can make the body reject the new liver, so they are usually avoided. Read why immunotherapy is avoided after a transplant. An active autoimmune illness may flare badly. Hepatitis B must be controlled with antiviral tablets first, under a hepatologist; it is controlled, never removed, so those tablets carry on.
When the liver is failing
With Child-Pugh C function, deep jaundice or repeated confusion, no drug treatment for the cancer is likely to help, and the liver itself is the main problem. Good symptom care, given alongside the family, is the right treatment then. It is not giving up.
If tablets were stopped because of side effects, tell the team. It changes what comes next.What we cannot say here
What this page cannot tell you
It cannot tell you whether one drug or two is right for you. That depends on your scans, endoscopy, liver tests and other illnesses, and only a medical oncologist who has seen them can weigh it. Nor can it say how long treatment will hold the cancer or how long anyone will live. Trials describe large groups, and no group figure predicts one person.
Where the evidence is thin
Most trials included only people with well-preserved liver function. For Child-Pugh B, the evidence for any immune drug is limited, and decisions rest on smaller studies and experience. A good team will say so plainly.
Mechanics, side effects and cost
How these drugs work and what side effects to expect are covered on the immunotherapy for liver cancer page. Costs vary with the drug, the brand and the hospital, so ask for a written, itemised estimate before you start.
Questions we are asked
Common questions about immunotherapy alone for liver cancer
Is a single immune drug as good as a combination?
Not for most people. In trials, the pairs did better than sorafenib, while single drugs did about as well as sorafenib. A single drug makes sense when a combination is not safe or would be too hard to tolerate, and that is a judgement your oncologist makes with you.
Can atezolizumab be given alone for liver cancer?
Not as a standard treatment for advanced liver cancer. Atezolizumab is given together with bevacizumab. If your plan lists atezolizumab without bevacizumab, ask your oncologist to explain why, because it would be an unusual choice that needs a clear reason.
Is durvalumab alone a reasonable choice?
It can be, for the right person. In its trial, durvalumab alone matched sorafenib with fewer side effects. It is often considered for people who cannot take bevacizumab and are not suited to the stronger two-drug immune combination. See the durvalumab medicine page.
Can nivolumab or pembrolizumab be used after sorafenib?
Yes, in some cases. Both have been used as a later step after tablets stop working. The evidence is mixed, so they are offered as options rather than standards. Read about second-line treatment for how that choice is made.
Is immunotherapy safe with cirrhosis?
It can be, if the cirrhosis is well compensated and liver tests are watched closely. Immune drugs can inflame the liver, which is harder to spot in a liver that is already scarred. Your team will check liver tests before every visit and act early if they rise.
What side effects matter most at home?
Loose motions that keep going, a new rash, yellow eyes, breathlessness, a cough that will not settle, or unusual tiredness. These can mean the immune system is attacking a healthy organ. Call your team the same day instead of waiting for the next appointment.
Is a single drug cheaper than a combination?
Often, because you pay for one drug instead of two, and lower-cost versions of some drugs are sold in India. Costs still vary with the brand and the hospital. Ask for a written, itemised estimate, and ask whether a scheme or insurance covers it.
Can CION give single-drug immunotherapy?
Yes. Immunotherapy is given at CION centres, and the tumour board reviews scans and reports before any plan is confirmed. Scans and endoscopy are arranged through accredited partners. Call the helpline to have a medical oncologist go through your reports.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Immunotherapy for Liver Cancer
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
- National Cancer Institute — Immunotherapy for Cancer
- National Cancer Institute — Liver Cancer Treatment
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Durvalumab plus tremelimumab for liver cancerThe two-drug immune combination, explainedChoosing between immunotherapy and tabletsHow immune drugs compare with sorafenib and lenvatinibSystemic treatment with Child-Pugh B liver functionWhen the liver is weaker and evidence is thinnerImmunotherapy with hepatitis B or cirrhosisThe extra safety checks these conditions need
Talk to us
Wondering whether one immune drug or two suits you?
Send us your scans, endoscopy and liver tests, and a medical oncologist will explain which option fits your situation and why. One helpline serves every CION centre.